184 related articles for article (PubMed ID: 36937522)
1. Plasma biomarkers for diagnosis of Alzheimer's disease and prediction of cognitive decline in individuals with mild cognitive impairment.
Kivisäkk P; Carlyle BC; Sweeney T; Trombetta BA; LaCasse K; El-Mufti L; Tuncali I; Chibnik LB; Das S; Scherzer CR; Johnson KA; Dickerson BC; Gomez-Isla T; Blacker D; Oakley DH; Frosch MP; Hyman BT; Aghvanyan A; Bathala P; Campbell C; Sigal G; Stengelin M; Arnold SE
Front Neurol; 2023; 14():1069411. PubMed ID: 36937522
[TBL] [Abstract][Full Text] [Related]
2. Plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross-sectional and longitudinal study in the AIBL cohort.
Chatterjee P; Pedrini S; Doecke JD; Thota R; Villemagne VL; Doré V; Singh AK; Wang P; Rainey-Smith S; Fowler C; Taddei K; Sohrabi HR; Molloy MP; Ames D; Maruff P; Rowe CC; Masters CL; Martins RN;
Alzheimers Dement; 2023 Apr; 19(4):1117-1134. PubMed ID: 36574591
[TBL] [Abstract][Full Text] [Related]
3. Plasma GFAP, NfL and pTau 181 detect preclinical stages of dementia.
Ingannato A; Bagnoli S; Mazzeo S; Giacomucci G; Bessi V; Ferrari C; Sorbi S; Nacmias B
Front Endocrinol (Lausanne); 2024; 15():1375302. PubMed ID: 38654932
[TBL] [Abstract][Full Text] [Related]
4. Plasma neurofilament light, glial fibrillary acid protein, and phosphorylated tau 181 as biomarkers for neuropsychiatric symptoms and related clinical disease progression.
Rabl M; Zullo L; Lewczuk P; Kornhuber J; Karikari TK; Blennow K; Zetterberg H; Bavato F; Quednow BB; Seifritz E; von Gunten A; Clark C; Popp J
Res Sq; 2024 Mar; ():. PubMed ID: 38562890
[TBL] [Abstract][Full Text] [Related]
5. Pathologic and cognitive correlates of plasma biomarkers in neurodegenerative disease.
Cousins KAQ; Phillips JS; Das SR; O'Brien K; Tropea TF; Chen-Plotkin A; Shaw LM; Nasrallah IM; Mechanic-Hamilton D; McMillan CT; Irwin DJ; Lee EB; Wolk DA
Alzheimers Dement; 2024 Jun; 20(6):3889-3905. PubMed ID: 38644682
[TBL] [Abstract][Full Text] [Related]
6. Longitudinal blood biomarker trajectories in preclinical Alzheimer's disease.
Yakoub Y; Ashton NJ; Strikwerda-Brown C; Montoliu-Gaya L; Karikari TK; Kac PR; Gonzalez-Ortiz F; Gallego-Rudolf J; Meyer PF; St-Onge F; Schöll M; Soucy JP; Breitner JCS; Zetterberg H; Blennow K; Poirier J; Villeneuve S;
Alzheimers Dement; 2023 Dec; 19(12):5620-5631. PubMed ID: 37294682
[TBL] [Abstract][Full Text] [Related]
7. Differential levels of plasma biomarkers of neurodegeneration in Lewy body dementia, Alzheimer's disease, frontotemporal dementia and progressive supranuclear palsy.
Chouliaras L; Thomas A; Malpetti M; Donaghy P; Kane J; Mak E; Savulich G; Prats-Sedano MA; Heslegrave AJ; Zetterberg H; Su L; Rowe JB; O'Brien JT
J Neurol Neurosurg Psychiatry; 2022 Jun; 93(6):651-658. PubMed ID: 35078917
[TBL] [Abstract][Full Text] [Related]
8. Plasma biomarkers of Alzheimer's disease and related dementias in American Indians: The Strong Heart Study.
Suchy-Dicey AM; Longstreth WT; Rhoads K; Umans J; Buchwald D; Grabowski T; Blennow K; Reiman E; Zetterberg H
Alzheimers Dement; 2024 Mar; 20(3):2072-2079. PubMed ID: 38215191
[TBL] [Abstract][Full Text] [Related]
9. Longitudinal associations of serum biomarkers with early cognitive, amyloid and grey matter changes.
De Meyer S; Blujdea ER; Schaeverbeke J; Reinartz M; Luckett ES; Adamczuk K; Van Laere K; Dupont P; Teunissen CE; Vandenberghe R; Poesen K
Brain; 2024 Mar; 147(3):936-948. PubMed ID: 37787146
[TBL] [Abstract][Full Text] [Related]
10. Alzheimer's Disease Plasma Biomarkers Distinguish Clinical Diagnostic Groups in Memory Clinic Patients.
Gerards M; Schild AK; Meiberth D; Rostamzadeh A; Vehreschild JJ; Wingen-Heimann S; Johannis W; Martino Adami P; Onur OA; Ramirez A; Karikari TK; Ashton NJ; Zetterberg H; Blennow K; Maier F; Jessen F
Dement Geriatr Cogn Disord; 2022; 51(2):182-192. PubMed ID: 35504263
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic value of plasma p-tau181, NfL, and GFAP in a clinical setting cohort of prevalent neurodegenerative dementias.
Baiardi S; Quadalti C; Mammana A; Dellavalle S; Zenesini C; Sambati L; Pantieri R; Polischi B; Romano L; Suffritti M; Bentivenga GM; Randi V; Stanzani-Maserati M; Capellari S; Parchi P
Alzheimers Res Ther; 2022 Oct; 14(1):153. PubMed ID: 36221099
[TBL] [Abstract][Full Text] [Related]
12. Plasma biomarkers of neurodegeneration in mild cognitive impairment with Lewy bodies.
Hamilton CA; O'Brien J; Heslegrave A; Laban R; Donaghy P; Durcan R; Lawley S; Barnett N; Roberts G; Firbank M; Taylor JP; Zetterberg H; Thomas A
Psychol Med; 2023 Dec; 53(16):7865-7873. PubMed ID: 37489795
[TBL] [Abstract][Full Text] [Related]
13. Blood biomarkers in mild cognitive impairment patients: Relationship between analytes and progression to Alzheimer disease dementia.
Silva-Spínola A; Lima M; Leitão MJ; Bernardes C; Durães J; Duro D; Tábuas-Pereira M; Santana I; Baldeiras I
Eur J Neurol; 2023 Jun; 30(6):1565-1573. PubMed ID: 36880887
[TBL] [Abstract][Full Text] [Related]
14. Plasma neurofilament light and phosphorylated tau 181 as biomarkers of Alzheimer's disease pathology and clinical disease progression.
Clark C; Lewczuk P; Kornhuber J; Richiardi J; Maréchal B; Karikari TK; Blennow K; Zetterberg H; Popp J
Alzheimers Res Ther; 2021 Mar; 13(1):65. PubMed ID: 33766131
[TBL] [Abstract][Full Text] [Related]
15. The role of plasma neurofilament light chain and glial fibrillary acidic protein in subjective cognitive decline and mild cognitive impairment.
Mazzeo S; Ingannato A; Giacomucci G; Bagnoli S; Cavaliere A; Moschini V; Balestrini J; Morinelli C; Galdo G; Emiliani F; Piazzesi D; Crucitti C; Frigerio D; Polito C; Berti V; Padiglioni S; Sorbi S; Nacmias B; Bessi V
Neurol Sci; 2024 Mar; 45(3):1031-1039. PubMed ID: 37723371
[TBL] [Abstract][Full Text] [Related]
16. An examination of a novel multipanel of CSF biomarkers in the Alzheimer's disease clinical and pathological continuum.
Van Hulle C; Jonaitis EM; Betthauser TJ; Batrla R; Wild N; Kollmorgen G; Andreasson U; Okonkwo O; Bendlin BB; Asthana S; Carlsson CM; Johnson SC; Zetterberg H; Blennow K
Alzheimers Dement; 2021 Mar; 17(3):431-445. PubMed ID: 33336877
[TBL] [Abstract][Full Text] [Related]
17. Serum GFAP differentiates Alzheimer's disease from frontotemporal dementia and predicts MCI-to-dementia conversion.
Oeckl P; Anderl-Straub S; Von Arnim CAF; Baldeiras I; Diehl-Schmid J; Grimmer T; Halbgebauer S; Kort AM; Lima M; Marques TM; Ortner M; Santana I; Steinacker P; Verbeek MM; Volk AE; Ludolph AC; Otto M
J Neurol Neurosurg Psychiatry; 2022 Apr; ():. PubMed ID: 35477892
[TBL] [Abstract][Full Text] [Related]
18. A Combination of Neurofilament Light, Glial Fibrillary Acidic Protein, and Neuronal Pentraxin-2 Discriminates Between Frontotemporal Dementia and Other Dementias.
Bolsewig K; Hok-A-Hin YS; Sepe FN; Boonkamp L; Jacobs D; Bellomo G; Paoletti FP; Vanmechelen E; Teunissen CE; Parnetti L; Willemse EAJ
J Alzheimers Dis; 2022; 90(1):363-380. PubMed ID: 36120776
[TBL] [Abstract][Full Text] [Related]
19. Cross-sectional and longitudinal evaluation of plasma glial fibrillary acidic protein to detect and predict clinical syndromes of Alzheimer's disease.
Ally M; Sugarman MA; Zetterberg H; Blennow K; Ashton NJ; Karikari TK; Aparicio HJ; Frank B; Tripodis Y; Martin B; Palmisano JN; Steinberg EG; Simkin I; Farrer LA; Jun GR; Turk KW; Budson AE; O'Connor MK; Au R; Goldstein LE; Kowall NW; Killiany R; Stern RA; Stein TD; McKee AC; Qiu WQ; Mez J; Alosco ML
Alzheimers Dement (Amst); 2023; 15(4):e12492. PubMed ID: 37885919
[TBL] [Abstract][Full Text] [Related]
20. Classification accuracy of blood-based and neurophysiological markers in the differential diagnosis of Alzheimer's disease and frontotemporal lobar degeneration.
Benussi A; Cantoni V; Rivolta J; Archetti S; Micheli A; Ashton N; Zetterberg H; Blennow K; Borroni B
Alzheimers Res Ther; 2022 Oct; 14(1):155. PubMed ID: 36229847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
